# OnCo record resectable-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/resectable-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "resectable-nsclc" ;
  schema:name "Resectable stage I to III non-small-cell lung cancer"@en ;
  schema:alternateName "Early-stage non-small-cell lung cancer"@en, "Operable lung cancer"@en, "Stage I, II and IIIA NSCLC"@en, "Perioperative NSCLC"@en ;
  schema:description "Lung cancer caught before it has spread is treated with surgery, now often keyhole or robotic and sometimes removing only part of a lobe. Immunotherapy given before and after the operation, or a targeted pill afterwards for EGFR or ALK tumours, cuts the chance of the cancer coming back by between a third and four fifths."@en ;
  schema:url <https://onco.cc/cancers/resectable-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lung_cancer_surgery> ;
  schema:citation <https://en.wikipedia.org/wiki/Lung_cancer_surgery>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/technologies/robotic-bronchoscopy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/vinorelbine/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:institutions <https://onco.cc/institutions/alliance-oncology/>, <https://onco.cc/institutions/jcog/>, <https://onco.cc/institutions/iaslc/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/lobectomy/>, <https://onco.cc/terms/segmentectomy/>, <https://onco.cc/terms/pneumonectomy/>, <https://onco.cc/terms/minimally-invasive-surgery/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/major-pathological-response/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/cancer-stage/>, <https://onco.cc/terms/bronchoscopy/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/trials/nct04025879/>, <https://onco.cc/trials/nct02486718/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/alina/>, <https://onco.cc/trials/calgb-140503/>, <https://onco.cc/trials/chisel/>, <https://onco.cc/trials/jcog0403/>, <https://onco.cc/trials/nlst-nelson/>, <https://onco.cc/trials/alchemist/> ;
  onco:people <https://onco.cc/people/patrick-forde/>, <https://onco.cc/people/jonathan-spicer/>, <https://onco.cc/people/tina-cascone/>, <https://onco.cc/people/heather-wakelee/>, <https://onco.cc/people/john-heymach/>, <https://onco.cc/people/enriqueta-felip/>, <https://onco.cc/people/roy-herbst/>, <https://onco.cc/people/wu-yi-long/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/>, <https://onco.cc/key-papers/paper-adaura-nejm-2020/>, <https://onco.cc/key-papers/paper-nlst-nejm-2011/> ;
  onco:pipeline <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/trials/nct04025879/>, <https://onco.cc/ideas/idea-tr2-ctdna-mrd-qualification/>, <https://onco.cc/ideas/idea-tr2-neoadjuvant-combo-platform/>, <https://onco.cc/ideas/idea-bio2-neoadjuvant-biomarker-engine/>, <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/technologies/robotic-bronchoscopy/> ;
  onco:standardOfCare <https://onco.cc/trials/calgb-140503/>, <https://onco.cc/terms/lobectomy/>, <https://onco.cc/terms/segmentectomy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/terms/minimally-invasive-surgery/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/trials/chisel/>, <https://onco.cc/trials/jcog0403/>, <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/trials/nct04025879/>, <https://onco.cc/trials/nct02486718/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/major-pathological-response/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/trials/alina/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/bronchoscopy/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tnm-staging/> .